Showing 2441-2450 of 5693 results for "".
- Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementiahttps://modernod.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition, according to a report in the American Journal of Managed Care. Some ophthalmic condition
- Novartis to Present New Data Highlighting Recent Safety-Specific Beovu Studies at EURETINA 2021https://modernod.com/news/novartis-to-present-new-data-highlighting-recent-safety-specific-beovu-studies-at-euretina-2021/2479502/At the upcoming EURETINA 2021 Virtual Congress, Novartis will present new data highlighting safety-specific Beovu studies, including: The Safety-Specific, Next-Generation Optical Coherence Tomography Analysis from HAWK: Preliminary Qualitative OCT Findings Associated with I
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- Coburn Technologies Launches Waterless Lens Deblocking System and Alloy Recovery Systemhttps://modernod.com/news/coburn-technologies-launches-waterless-lens-deblocking-system-and-alloy-recovery-system/2479494/Coburn Technologies has officially launched the Reimagine Campaign to announce new technology advancements in lens processing. Coburn has developed a completely waterless lens deblocking system and a first-of-its-kind alloy recovery system for labs that use alloy for lens processing.
- ARVO Women’s Leadership Development Program Welcomes Class of 2021https://modernod.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/The Association for Research in Vision and Ophthalmology (ARVO) recognized the 2021 class of its Women’s Leadership Development Program (WLDP). The program, provided through the support of Aerie Pharmaceuticals, is an interactive, year-long learning experience focused on leadership skill developm
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2021 Online Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-2021-online-conference/2479453/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 2021 Online Conference at www.nora2021.com. The conference will be available live online from Thursday, October 14 to Saturday, October 16, with select presenta
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- Journal Highlights Desirable PK/PD Profiles of THR-687 and THR-149https://modernod.com/news/journal-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149/2479450/Oxurion NV announced the publication of two related papers in the Journal of Pharmacokinetics and Pharmacodynamics entitled “Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach.” These papers describe the pharmacoki
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ